ProNoxis AB was founded in 2009 by LU Bioscience AB (LUBio), Karolinska Development AB, and Redoxis AB, as a Redoxis spin-off focusing on developing anti-inflammatory therapeutics targeting activation of the NADPH oxidase complex (NOX2).

ProNoxis focuses on the development of small-molecule drugs to treat chronic inflammation. We combine the drug development and project management expertise of LUBio and Karolinska Development with the scientific expertise of Redoxis.